Inclusion Criteria:

          -  Pathologically confirmed non small cell lung cancer (NSCLC), not previously treated,
             with a plan to undergo surgery

          -  Stage I-IIIA (stage I tumors must be >= 4 cm) per AJCC 8th edition

          -  Tumor sample must be available for PD-L1 testing; archival tissue within 3 months of
             study enrollment will be used; if archival tissue is unavailable, a fresh biopsy will
             be taken

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  While blood cells 2000/ul or more

          -  Absolute neutrophil count 1500/ul or more

          -  Platelets 100,000/ul or more

          -  Hemoglobin 9 g/dl or more; (transfusion permitted)

          -  Bilirubin less than or equal to 1.5 x the upper limit of normal (except subjects with
             Gilbert syndrome, who can have total bilirubin < 3 mg/dl)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal
             to 3 x the upper limit of normal

          -  Glomerular filtration rate (GFR) greater than or equal to 40 ml/min using the
             Cockcroft-Gault formula or serum creatinine less than or equal to 1.5 x (ULN) upper
             limit of normal

          -  Women of reproductive potential should have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin
             [HCG]) within 21 days of the study enrollment

          -  Women of reproductive potential must use highly effective contraception methods to
             avoid pregnancy for 23 weeks after the last dose of study drugs; "women of
             reproductive potential" is defined as any female who has experienced menarche and who
             has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or
             who is not postmenopausal; menopause is defined clinically as 12 months of amenorrhea
             in a woman over 45 in the absence of other biological or physiological causes; in
             addition, women under the age of 55 must have a documented serum follicle stimulating
             hormone (FSH) level more than 40 mIU/mL

          -  Men of reproductive potential who are sexually active with women of reproductive
             potential must use any contraceptive method with a failure rate of less than 1% per
             year; men who are receiving the study medications will be instructed to adhere to
             contraception for 31 weeks after the last dose of study drugs; men who are azoospermic
             do not require contraception

          -  All subjects must be able to comprehend and sign a written informed consent document

        Exclusion Criteria:

          -  Patients who have participated in a study with an investigational agent or device
             within 2 weeks of enrollment

          -  Any prior radiotherapy to the lung

          -  Any prior treatment for NSCLC

          -  Epidermal growth factor receptor (EGFR) or alkaline phosphatase (ALK) activating
             alteration

          -  Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other
             antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint
             pathways

          -  Any history of a sever hypersensitivity reaction to any monoclonal antibody

          -  Any history of allergy to the study drug components

          -  Any concurrent malignancies- exceptions include- basal cell carcinoma of the skin,
             squamous cell carcinoma of the skin, superficial bladder cancer or in situ cervical
             cancer that has undergone potentially curative therapy; patients with a history of
             other prior malignancy must have been treated with curative intent and must have
             remained disease-free for 3 years post-diagnosis

          -  Participants with an active autoimmune disease or any other condition requiring
             systemic treatment with either corticosteroids within 14 days (> 10 mg daily
             prednisone equivalent) or other immunosuppressive medications within 30 days of
             randomization. Inhaled or topical steroids, and adrenal replacement steroid doses > 10
             mg daily prednisone equivalent, are permitted in the absence of active autoimmune
             disease.

          -  Participants with type I diabetes mellitus, hypothyroidism only requiring hormone
             replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring
             systemic treatment, or conditions not expected to recur in the absence of an external
             trigger are permitted to enroll.• Patients with evidence of interstitial lung disease
             or active, non-infectious pneumonitis. Patients with a history of interstitial lung
             disease or non-infectious pneumonitis requiring treatment with steroids are also
             excluded.

          -  Patients with a known human immunodeficiency virus infection (HIV 1/2 antibodies) or
             acquired immunodeficiency syndrome (HIV/AIDS), active hepatitis B (e.g., hepatitis B
             surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV]
             ribonucleic acid [RNA] [qualitative] is detected)

          -  Patients who have received a live vaccine within 30 days prior initiation of the
             systemic regimen

          -  Patients must not be receiving any other investigational agents

          -  Patients with uncontrolled intercurrent illnesses including, but not limited to an
             active infection requiring systemic therapy or a known psychiatric or substance abuse
             disorder(s) that would interfere with cooperation with the requirements of the trial

          -  Women must not be pregnant (as above) or breastfeeding